GSK's Phase III trial of shingles vaccine candidate meets primary endpoint

GlaxoSmithKline (GSK) has reported that its Phase III trial designed to evaluate the efficacy of HZ/su, an investigational vaccine for the prevention of shingles, met its primary endpoint.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news